On September 23, 2021 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that its board of directors has authorized the repurchase of $3 billion of shares of its common stock in the open market or in negotiated transactions (Press release, Thermo Fisher Scientific, SEP 23, 2021, View Source [SID1234590232]). The authorization has no expiration date. This replaces the company’s existing repurchase authorization, of which $500 million was remaining.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!